Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
株式のランク #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Regulus Therapeutics Inc. (RGLS)

カテゴリー

Regulus Therapeutics Inc.(RGLS)のP/S比率
September 2026 時点のP/S比率 TTM: 0.00
Regulus Therapeutics Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0.00 です。2023 年末時点でのP/S比率は 0.00 でした。
Regulus Therapeutics Inc. の P/S 比率の履歴(2010 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 4.72 109.88%
2019 2.25 -98.00%
2018 112.61 -92.50%
2017 1.50K 1,409.28%
2016 99.52 360.84%
2015 21.60 -76.58%
2014 92.22 534.60%
2013 14.53 256.69%
2012 4.07 5,109.59%
2011 0.08 -37.59%
2010 0.13 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH